{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:20:16Z","timestamp":1791559216588,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11523-021-00802-9","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T07:58:49Z","timestamp":1615276729000},"page":"295-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Follows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606\u201319.","journal-title":"Nat Rev Genet"},{"key":"802_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627\u201344.","journal-title":"Nat Rev Drug Discov."},{"key":"802_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-201X.2004.01382.x","volume":"183","author":"PR Shepherd","year":"2005","unstructured":"Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand. 2005;183:3\u201312.","journal-title":"Acta Physiol Scand"},{"key":"802_CR4","first-page":"79","volume":"347","author":"PK Vogt","year":"2010","unstructured":"Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol. 2010;347:79\u2013104.","journal-title":"Curr Top Microbiol Immunol"},{"key":"802_CR5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988\u20131004.","journal-title":"Nat Rev Drug Discov."},{"key":"802_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","volume":"13","author":"JH Schatz","year":"2011","unstructured":"Schatz JH. Targeting the PI3K\/AKT\/mTOR pathway in non-Hodgkin\u2019s lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13:398.","journal-title":"Curr Oncol Rep."},{"key":"802_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","volume":"29","author":"H Nogai","year":"2011","unstructured":"Nogai H, D\u00f6rken B, Lenz G. Pathogenesis of non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2011;29:1803\u201311.","journal-title":"J Clin Oncol"},{"key":"802_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","volume":"26","author":"MA Lunning","year":"2012","unstructured":"Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev. 2012;26:279\u201388.","journal-title":"Blood Rev"},{"key":"802_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol. 2019;103:152\u201363.","journal-title":"Eur J Haematol"},{"key":"802_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"802_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112\u201320.","journal-title":"Blood"},{"key":"802_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","volume":"133","author":"C Casulo","year":"2019","unstructured":"Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133:1540\u20137.","journal-title":"Blood"},{"key":"802_CR13","doi-asserted-by":"crossref","unstructured":"Casulo C, Barr PM. How I treat in brief: early relapsing follicular lymphoma. https:\/\/www.ashclinicalnews.org\/education\/how-i-treat-in-brief\/treat-brief-early-relapsing-follicular-lymphoma\/. Accessed 13 July 2020.","DOI":"10.1182\/blood-2018-08-822148"},{"key":"802_CR14","first-page":"14875","volume":"8","author":"Y Ma","year":"2015","unstructured":"Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Int J Clin Exp Pathol. 2015;8:14875\u201384.","journal-title":"Int J Clin Exp Pathol."},{"key":"802_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00277-013-1770-9","volume":"92","author":"ZZ Xu","year":"2013","unstructured":"Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, et al. Activation of the PI3K\/AKT\/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol. 2013;92:1351\u20138.","journal-title":"Ann Hematol"},{"key":"802_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/1471-2407-14-565","volume":"14","author":"OI Yahiaoui","year":"2014","unstructured":"Yahiaoui OI, Nun\u00e8s JA, Castanier C, Devillier R, Broussais F, Fabre AJ, et al. Constitutive AKT activation in follicular lymphoma. BMC Cancer. 2014;14:565.","journal-title":"BMC Cancer."},{"key":"802_CR17","unstructured":"US Food and Drug Administration. COPIKTRA (duvelisib) highlights of prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf. Accessed 13 July 2020."},{"key":"802_CR18","unstructured":"US Food and Drug Administration. ZYDELIG (idelalisib) highlights of prescribing information. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206545lbl.pdf. Accessed 13 July 2020."},{"key":"802_CR19","unstructured":"US Food and Drug Administration. ALIQOPA (copanlisib) highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209936s004lbl.pdf. Accessed 13 July 2020."},{"key":"802_CR20","first-page":"821","volume":"31","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology. 2017;31:821\u20138.","journal-title":"Oncology"},{"key":"802_CR21","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutr\u00e9","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779\u201386.","journal-title":"Leuk Lymphoma"},{"key":"802_CR22","unstructured":"US Food and Drug Administration. FDA alerts healthcare professionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medicines. 2016. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm490618.htm. Accessed 13 July 2020."},{"key":"802_CR23","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1097\/HS9.0000000000000039","volume":"2","author":"SE Coutre","year":"2018","unstructured":"Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, et al. Idelalisib in combination with rituximab or bendamustine or both in patients with relapsed\/refractory chronic lymphocytic leukemia. Hemasphere. 2018;2:e39.","journal-title":"Hemasphere."},{"key":"802_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/ajh.25634","volume":"94","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Am J Hematol. 2019;94:1325\u201334.","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"802_CR25","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2019.37.15_suppl.7506","volume":"37","author":"NH Fowler","year":"2019","unstructured":"Fowler NH, Samaniego F, Jurczak W, Lech-Maranda E, Ghosh N, Patten P, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed\/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study. J Clin Oncol. 2019;37(15_suppl):7506.","journal-title":"J Clin Oncol"},{"issue":"2","key":"802_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/10428194.2020.1832660","volume":"62","author":"M Coleman","year":"2021","unstructured":"Coleman M, Belada D, Casasnovas RO, Gressin R, Lee HP, Mehta A, et al. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K\u03b4 inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma. 2021;62(2):368\u201376.","journal-title":"Leuk Lymphoma."},{"key":"802_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134:636\u201340.","journal-title":"Blood"},{"issue":"15_suppl","key":"802_CR28","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles GA, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL). J Clin Oncol. 2020;38(15_suppl):8008.","journal-title":"J Clin Oncol"},{"key":"802_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1_suppl","key":"802_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bartlett NL, Assouline S, Yoon SS, Bosch FX, Sehn LH, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(1_suppl):6.","journal-title":"Blood"},{"issue":"15_suppl","key":"802_CR31","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2020.38.15_suppl.8009","volume":"38","author":"M Hutchings","year":"2020","unstructured":"Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, et al. Epcoritamab (GEN3013; DuoBody-CD3\u2009\u00d7\u2009CD20) to induce complete response in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL): complete dose escalation data and efficacy results from a phase I\/II trial. J Clin Oncol. 2020;38(15_suppl):8009.","journal-title":"J Clin Oncol"},{"key":"802_CR32","unstructured":"US Food and Drug Administration. FDA granted accelerated approval to tazemetostat for follicular lymphoma. 2020. https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma. Accessed 13 July 2020."},{"key":"802_CR33","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","volume":"12","author":"N Liu","year":"2013","unstructured":"Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12:2319\u201330.","journal-title":"Mol Cancer Ther"},{"key":"802_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann Oncol. 2016;27:1928\u201340.","journal-title":"Ann Oncol"},{"key":"802_CR35","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898\u2013905.","journal-title":"J Clin Oncol"},{"key":"802_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows G, Lenz G, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95:362\u201371.","journal-title":"Am J Hematol"},{"key":"802_CR37","unstructured":"US Food and Drug Administration. ALIQOPA (copanlisib) highlights of prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf. Accessed 13 July 2020."},{"issue":"8_suppl","key":"802_CR38","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1538-7445.AM10-4478","volume":"70","author":"N Liu","year":"2010","unstructured":"Liu N, Haegebarth A, Bull C, Schatz C, Wiehr S, Pichler BJ, et al. BAY 80\u20136946, a highly potent and efficacious PI3K class I inhibitor, induces complete tumor regression or tumor stasis in tumor xenograft models with PIK3CA mutant or PTEN deletion. Cancer Res. 2010;70(8_suppl):4478.","journal-title":"Cancer Res."},{"key":"802_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.cmet.2019.03.010","volume":"29","author":"A Molinaro","year":"2019","unstructured":"Molinaro A, Becattini B, Mazzoli A, Bleve A, Radici L, Maxvall I, et al. Insulin-driven PI3K-AKT signaling in the hepatocyte is mediated by redundant PI3K\u03b1 and PI3K\u03b2 activities and is promoted by RAS. Cell Metab. 2019;29:1400\u20139.e5.","journal-title":"Cell Metab"},{"key":"802_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling. Cell. 2006;125:733\u201347.","journal-title":"Cell"},{"key":"802_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang X, Liu G, Guo J, Su Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483\u201396.","journal-title":"Int J Biol Sci."},{"key":"802_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cmet.2010.02.002","volume":"11","author":"VR Sopasakis","year":"2010","unstructured":"Sopasakis VR, Liu P, Suzuki R, Kondo T, Winnay J, Tran TT, et al. Specific roles of the p110\u03b1 isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab. 2010;11:220\u201330.","journal-title":"Cell Metab"},{"key":"802_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1634\/theoncologist.2015-0248","volume":"21","author":"KH Khan","year":"2016","unstructured":"Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, et al. Hyperglycemia and phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin (PI3K\/AKT\/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist. 2016;21:855\u201360.","journal-title":"Oncologist."},{"key":"802_CR44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-16-1080","volume":"7","author":"D Juric","year":"2017","unstructured":"Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov. 2017;7:704\u201315.","journal-title":"Cancer Discov"},{"key":"802_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A Phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2\u2212 metastatic breast cancer. Clin Cancer Res. 2017;23:26\u201334.","journal-title":"Clin Cancer Res"},{"key":"802_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282\u201390.","journal-title":"J Clin Oncol"},{"key":"802_CR47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/1535-7163.MCT-19-0466","volume":"19","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D, et al. On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther. 2020;19:468\u201378.","journal-title":"Mol Cancer Ther"},{"key":"802_CR48","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1038\/bjc.2014.162","volume":"110","author":"S Han","year":"2014","unstructured":"Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, et al. Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110:2560\u20138.","journal-title":"Br J Cancer"},{"key":"802_CR49","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.humpath.2017.09.012","volume":"69","author":"K Wang","year":"2017","unstructured":"Wang K, Shen T, Siegal GP, Wei S. The CD4\/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol. 2017;69:110\u20137.","journal-title":"Hum Pathol"},{"key":"802_CR50","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.21037\/jtd-19-3414a","volume":"12","author":"AB Schulze","year":"2020","unstructured":"Schulze AB, Evers G, G\u00f6rlich D, Mohr M, Marra A, Hillejan L, et al. Tumor infiltrating T cells influence prognosis in stage I\u2013III non-small cell lung cancer. J Thorac Dis. 2020;12:1824\u201342.","journal-title":"J Thorac Dis."},{"issue":"15_suppl","key":"802_CR51","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1200\/jco.2011.29.15_suppl.3035","volume":"29","author":"A Patnaik","year":"2011","unstructured":"Patnaik A, Appleman LJ, Mountz JM, Ramanathan RK, Beeram M, Tolcher AW, et al. A first-in-human Phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase. J Clin Oncol. 2011;29(15_suppl):3035.","journal-title":"J Clin Oncol"},{"key":"802_CR52","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169\u201378.","journal-title":"Ann Oncol"},{"key":"802_CR53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2017.07.002","volume":"17","author":"M Mustafa Ali","year":"2017","unstructured":"Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, et al. Grade 3 follicular lymphoma: outcomes in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:797\u2013803.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"802_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clml.2018.11.010","volume":"19","author":"NN Shah","year":"2019","unstructured":"Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, et al. Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen. Clin Lymphoma Myeloma Leuk. 2019;19:95\u2013102.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"802_CR55","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184\u201397.","journal-title":"Leukemia"},{"key":"802_CR56","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417\u201329.","journal-title":"N Engl J Med"},{"key":"802_CR57","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med"},{"key":"802_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","volume":"130","author":"T Erdmann","year":"2017","unstructured":"Erdmann T, Klener P, Lynch JT, Grau M, Vo\u010dkov\u00e1 P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310\u201322.","journal-title":"Blood"},{"key":"802_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","volume":"31","author":"J Paul","year":"2017","unstructured":"Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, et al. Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT. Cancer Cell. 2017;31:64\u201378.","journal-title":"Cancer Cell"},{"issue":"1_suppl","key":"802_CR60","first-page":"1256","volume":"130","author":"F Morschhauser","year":"2017","unstructured":"Morschhauser F, Awada A, Machiels JP, Salles GA, Rottey S, Rule S, et al. Pharmacodynamic study of copanlisib in patients with non-Hodgkin\u2019s lymphoma and advanced solid tumors: confirmation of on-target PI3K inhibitory activity. Blood. 2017;130(1_suppl):1256.","journal-title":"Blood"},{"key":"802_CR61","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","volume":"21","author":"GI Shapiro","year":"2015","unstructured":"Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res. 2015;21:1888\u201395.","journal-title":"Clin Cancer Res"},{"key":"802_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:77\u201386.","journal-title":"Clin Cancer Res"},{"key":"802_CR63","doi-asserted-by":"publisher","first-page":"30392","DOI":"10.1074\/jbc.M103702200","volume":"276","author":"M Montagnani","year":"2001","unstructured":"Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179. J Biol Chem. 2001;276:30392\u20138.","journal-title":"J Biol Chem"},{"key":"802_CR64","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1681\/ASN.2006050541","volume":"18","author":"T Quaschning","year":"2007","unstructured":"Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic\/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol. 2007;18:730\u201340.","journal-title":"J Am Soc Nephrol"},{"key":"802_CR65","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00109-011-0798-3","volume":"89","author":"JM Ha","year":"2011","unstructured":"Ha JM, Kim YW, Lee DH, Yun SJ, Kim EK, Hye Jin I, et al. Regulation of arterial blood pressure by Akt1-dependent vascular relaxation. J Mol Med (Berl). 2011;89:1253\u201360.","journal-title":"J Mol Med (Berl)."},{"key":"802_CR66","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCRESAHA.108.189316","volume":"104","author":"JD Symons","year":"2009","unstructured":"Symons JD, McMillin SL, Riehle C, Tanner J, Palionyte M, Hillas E, et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res. 2009;104:1085\u201394.","journal-title":"Circ Res"},{"key":"802_CR67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/cvr\/cvq349","volume":"89","author":"Q Yu","year":"2011","unstructured":"Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011;89:516\u201324.","journal-title":"Cardiovasc Res"},{"key":"802_CR68","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","volume":"39","author":"AS Weidner","year":"2015","unstructured":"Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39:1661\u20137.","journal-title":"Am J Surg Pathol"},{"key":"802_CR69","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ajh.25228","volume":"93","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, et al. Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018;93:1311\u20137.","journal-title":"Am J Hematol"},{"key":"802_CR70","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.2147\/OTT.S142264","volume":"11","author":"FA Mensah","year":"2018","unstructured":"Mensah FA, Blaize JP, Bryan LJ. Spotlight on copanlisib and its potential in the treatment of relapsed\/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018;11:4817\u201327.","journal-title":"Onco Targets Ther."},{"key":"802_CR71","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2217\/fon-2020-0195","volume":"16","author":"M Narkhede","year":"2020","unstructured":"Narkhede M, Cheson BD. Copanlisib in the treatment of non-Hodgkin lymphoma. Future Oncol. 2020;16:1947\u201355.","journal-title":"Future Oncol."},{"key":"802_CR72","unstructured":"Zinzani PL, Dreyling M, Lepp\u00e4 S, Santoro A, Pedersen M, Buvaylo V, et al. Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent non-Hodgkin lymphoma. 25th Congress of the European Hematology Association (Virtual Edition), June 11\u201314, 2020. Poster EP1171."},{"key":"802_CR73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/1472-6963-14-274","volume":"14","author":"L Benjamin","year":"2014","unstructured":"Benjamin L, Buthion V, Vidal-Tr\u00e9can G, Briot P. Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts. BMC Health Serv Res. 2014;14:274.","journal-title":"BMC Health Serv Res."},{"key":"802_CR74","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1080\/10428194.2019.1594217","volume":"60","author":"AYL Zackon","year":"2019","unstructured":"Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, et al. Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. Leuk Lymphoma. 2019;60:2356\u201364.","journal-title":"Leuk Lymphoma"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00802-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:19:49Z","timestamp":1778494789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00802-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00802-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"3 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bayer AG provided funding support for the medical writing assistance received for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JM has received consulting fees from Alexion, Bayer, BeiGene, Bristol-Myers Squibb, Fosun Kite, Gilead\/Kite Pharma, Innovent, Janssen, Juno\/Celgene, Kyowa, Pfizer, Pharmacyclics, and Seattle Genetics; research funding from Bayer, Celgene, Genentech, Gilead\/Kite Pharma, Incyte, Janssen, Merck, Millennium, Portola, Pharmacyclics, and Seattle Genetics; honoraria from Kyowa and Seattle Genetics; and speaker\u2019s bureau fees from AbbVie, Acrotech\/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene\/Bristol-Myers Squibb, Genentech\/Roche, Gilead\/Kite Pharma, Kyowa, Pharmacyclics\/Janssen, Seattle Genetics, and Verastem. GAF reports consultancy and lecturing fees from AbbVie, AstraZeneca, Bayer, Janssen, and Roche. LJN has received honoraria from Bayer, Bristol-Myers Squibb\/Celgene, Genentech, Janssen, Kite\/Gilead, Novartis, Pfizer, and TG Therapeutics; and research support from Bristol-Myers Squibb\/Celgene, Genentech, Janssen, Novartis, Pfizer, and TG Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors provided insight into the development of this manuscript and provided critical review of each draft. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}